Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

7
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
7
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

150
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
150

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining topological robustness in optical polarization fields through a generalized skyrmion number.

Nature communications·2026
Same author

Comparative analysis of morphology and chloroplast genomes in endangered plant <i>Madhuca pasquieri</i> and two congeneric plants: revealing phylogenetic relationships.

Frontiers in plant science·2026
Same author

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
Same author

CT - derived fractional flow reserve can predict recurrent ischemia in patients with MCA stenosis.

Frontiers in neurology·2026
Same author

Reliability and Consistency Analysis of Multiple Instruments for Scoliosis Screening in Adolescent Males: A Comparative Study of Instrument Accuracy.

Studies in health technology and informatics·2026
Same author

Motionless speckle reduction using a three-dimensional printed micro-optical structure.

Optics express·2026

Related Experiment Video

Updated: Jun 6, 2025

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

2.9K

HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.

Matthew S Durstenfeld1, Anjali Thakkar2, Diane Jeon2

  • 1Division of Cardiology at ZSFG and Department of Medicine University of California, San Francisco (UCSF) San Francisco CA USA.

Journal of the American Heart Association
|November 22, 2024
PubMed
Summary

People with HIV diagnosed with heart failure (HF) face higher mortality rates, often due to non-cardiovascular causes like substance use. This study highlights disparities in HF care within safety-net systems.

Keywords:
HIVclinical outcomesheart failuremortality

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.4K
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

16.6K

Related Experiment Videos

Last Updated: Jun 6, 2025

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

2.9K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.4K
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

16.6K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • HIV infection is a known risk factor for heart failure (HF).
  • Data on HF phenotypes and outcomes in people with HIV (PWH) within safety-net systems are limited.
  • Safety-net systems care for a significant portion of PWH in the US.

Purpose of the Study:

  • To compare HF phenotypes, mortality, and causes of death in PWH versus those without HIV.
  • To investigate HF outcomes within a large municipal safety-net system.
  • To understand the specific challenges faced by PWH with HF in under-resourced healthcare settings.

Main Methods:

  • Retrospective analysis of an electronic health record cohort (2001-2019) of individuals with HF.
  • Linked EHR data with the National Death Index Plus for mortality outcomes.
  • Compared HF phenotypes, all-cause mortality, HF hospitalization, and causes of death between PWH and HIV-uninfected individuals.

Main Results:

  • PWH were diagnosed with HF 10 years younger on average and had a higher proportion with reduced ejection fraction.
  • HIV was associated with a 55% increased risk of all-cause mortality (HR 1.55) and lower odds of HF hospitalization (OR 0.51).
  • Causes of death in PWH with HF were less often cardiovascular and more frequently attributed to substance use.

Conclusions:

  • In safety-net systems, HIV infection is linked to significantly higher mortality among HF patients.
  • Despite lower HF hospitalization rates, PWH with HF experience worse survival.
  • Non-cardiovascular causes, including substance use and HIV-related conditions, contribute to excess mortality in this population.